Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges

被引：7
作者：
Li, Celine Man Ying [1 ,2 ]
Li, Runhao [2 ,3 ,4 ]
Drew, Paul [1 ,2 ]
Price, Timothy [2 ,3 ,4 ]
Smith, Eric [1 ,2 ,3 ,4 ]
Maddern, Guy J. [1 ,2 ]
Tomita, Yoko [2 ,3 ,4 ]
Fenix, Kevin [1 ,2 ]
机构：
[1] Univ Adelaide, Adelaide Med Sch, Dept Surg, Adelaide, SA 5005, Australia
[2] Queen Elizabeth Hosp, Basil Hetzel Inst Translat Hlth Res, Woodville, SA 5011, Australia
[3] Queen Elizabeth Hosp, Med Oncol, Woodville, SA 5011, Australia
[4] Univ Adelaide, Woodville, SA 5011, Australia
来源：
CANCER TREATMENT REVIEWS | 2024年 / 122卷
关键词：
CIK cell therapy; Adoptive cell therapies; Colorectal cancer; Cancer treatment; Cytokine induced killer cells; NK T cells; Immunotherapy; LUNG-CANCER; ANTITUMOR-ACTIVITY; OPEN-LABEL; T-CELLS; IMMUNOTHERAPY; CHEMOTHERAPY; EFFICACY; SURVIVAL; CYTOTOXICITY; PREDICTS;
D O I：
10.1016/j.ctrv.2023.102665
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Colorectal cancer (CRC) remains a significant global health burden and is the second leading cause of cancer related death. Cytokine induced killer (CIK) cell therapy is an immunotherapy which has the potential to meet this need. Clinical trials of CIK cell therapy for the management of CRC have reported improved clinical outcomes. However, production and delivery protocols varied significantly, and many studies were reported only in Chinese language journals. Here we present the most comprehensive review of the clinical CIK cell therapy trials for CRC management to date. We accessed both English and Chinese language clinical studies, and summarise how CIK cell therapy has been implemented, from manufacturing to patient delivery. We discuss current challenges that impede wider adoption of CIK cell therapy in CRC management.
引用
收藏
页数：11
相关论文
共 157 条
  • [1] Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
    Aldarouish, Mohanad
    Su, Xiangyu
    Qiao, Jianbing
    Gao, Chanchan
    Chen, Yan
    Dai, Anwei
    Zhang, Tianyu
    Shu, Yongqian
    Wang, Cailian
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2019, 33
  • [2] American Cancer Society, 2023, Cancer Facts Figures 2023
  • [3] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
    Andre, T.
    Shiu, K-K
    Kim, T. W.
    Jensen, B., V
    Jensen, L. H.
    Punt, C.
    Smith, D.
    Garcia-Carbonero, R.
    Benavides, M.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Bendell, J.
    Le, D. T.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Marinello, P.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2207 - 2218
  • [4] [Anonymous], SuperCulture L500
  • [5] Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines
    Azadi, Ali
    Golchini, Alireza
    Delazar, Sina
    Abarghooi Kahaki, Fatemeh
    Dehnavi, Seyed Mohsen
    Payandeh, Zahra
    Eyvazi, Shirin
    [J]. BIOLOGICAL PROCEDURES ONLINE, 2021, 23 (01)
  • [6] Baker J, 2005, BLOOD, V106, p310A
  • [7] Bian J, 2013, Chin J Surg Onco, P306
  • [8] Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
  • [9] Bremm M, 2019, Cells Front Immunol, V10
  • [10] Cai P, 2017, World Latest Med Inf, V17, P155
12345678910